1887

Abstract

Our previous screening of 50 240 structurally diverse compounds led to the identification of 39 influenza A virus infection inhibitors (Kao R.Y., Yang D., Lau L.S., Tsui W.H., Hu L. et al. Nat Biotechnol 2010;28:600–605). Further screening of these compounds against common respiratory viruses led to the discovery of compound FA-613. This inhibitor exhibited low micromolar antiviral activity against various influenza A and B virus strains, including the highly pathogenic influenza A strains H5N1 and H7N9, enterovirus A71, respiratory syncytial virus, human rhinovirus A, SARS- and MERS-coronavirus. No significant cellular toxicity was observed at the effective concentrations. Animal studies showed an improved survival rate in BALB/c mice that received intranasal FA-613 treatments against a lethal dose infection of A/HK/415742Md/2009 (H1N1). Further cell-based assays indicated that FA-613 interfer with the de novo pyrimidine biosynthesis pathway by targeting the dihydroorotate dehydrogenase. Surprisingly, FA-613 lost its antiviral potency in the interferon-deficient Vero cell line, while maintaining its inhibitory activity in an interferon-competent cell line which showed elevated expression of host antiviral genes when infected in the presence of FA-613. Further investigation of the specific connection between pyrimidine synthesis inhibition and the induction of host innate immunity might aid clinical development of this type of drug in antiviral therapies. Therefore, in acute cases of respiratory tract infections, when rapid diagnostics of the causative agent are not readily available, an antiviral drug with properties like FA-613 could prove to be very valuable.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000758
2017-05-30
2019-12-05
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/5/946.html?itemId=/content/journal/jgv/10.1099/jgv.0.000758&mimeType=html&fmt=ahah

References

  1. Mizgerd JP. Lung infection—a public health priority. PLoS Med 2006;3:e76 [CrossRef][PubMed]
    [Google Scholar]
  2. WHO The World Health Report 2002, no. 2.vol. 16 2002
    [Google Scholar]
  3. Bryce J, Boschi-Pinto C, Shibuya K, Black RE.WHO Child Health Epidemiology Reference Group WHO estimates of the causes of death in children. Lancet 2005;365:1147–1152 [CrossRef][PubMed]
    [Google Scholar]
  4. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086–5096 [CrossRef][PubMed]
    [Google Scholar]
  5. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics 2008;26:911–924[PubMed][CrossRef]
    [Google Scholar]
  6. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5:659–671 [CrossRef][PubMed]
    [Google Scholar]
  7. Esposito S, Gasparini R, Bosis S, Marchisio P, Tagliabue C et al. Clinical and socio-economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin Microbiol Infect 2005;11:933–936 [CrossRef][PubMed]
    [Google Scholar]
  8. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003;163:487–494 [CrossRef][PubMed]
    [Google Scholar]
  9. Hsiao C-J, Cherry DK, Beatty PC, Rechtsteiner E A. National ambulatory medical care survey: 2007 summary. Natl Health Stat Report 2010;no. 27:1–32
    [Google Scholar]
  10. Turner RB. Epidemiology, pathogenesis, and treatment of the common cold. Ann Allergy Asthma Immunol 1997;78:531–539 [CrossRef][PubMed]
    [Google Scholar]
  11. Ryu WS, Kang B, Hong J, Hwang S, Kim A et al. Enterovirus 71 infection with central nervous system involvement, South Korea. Emerg Infect Dis 2010;16:1764–1766 [CrossRef][PubMed]
    [Google Scholar]
  12. Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A et al. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of Enterovirus 71. Microbiol Immunol 2002;46:621–627 [CrossRef][PubMed]
    [Google Scholar]
  13. Zhang Q, Macdonald NE, Smith JC, Cai K, Yu H et al. Severe enterovirus type 71 nervous system infections in children in the Shanghai region of China: clinical manifestations and implications for prevention and care. Pediatr Infect Dis J 2014;33:482–487 [CrossRef][PubMed]
    [Google Scholar]
  14. Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther 2011;9:27–32 [CrossRef][PubMed]
    [Google Scholar]
  15. Patick AK. Rhinovirus chemotherapy. Antiviral Res 2006;71:391–396 [CrossRef]
    [Google Scholar]
  16. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010;9:1097–1105 [CrossRef][PubMed]
    [Google Scholar]
  17. Kao RY, Yang D, Lau LS, Tsui WH, Hu L et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010;28:600–605 [CrossRef][PubMed]
    [Google Scholar]
  18. Bonavia A, Franti M, Pusateri Keaney E, Kuhen K, Seepersaud M et al. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci USA 2011;108:6739–6744 [CrossRef][PubMed]
    [Google Scholar]
  19. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci USA 2011;108:5777–5782 [CrossRef][PubMed]
    [Google Scholar]
  20. Wachsman M, Hamzeh FM, Assadi NB, Lietman PS. Antiviral activity of inhibitors of pyrimidine de-novo biosynthesis. Antivir Chem Chemother 1996;7:7–13 [CrossRef]
    [Google Scholar]
  21. Lucas-Hourani M, Dauzonne D, Jorda P, Cousin G, Lupan A et al. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog 2013;9:e1003678 [CrossRef][PubMed]
    [Google Scholar]
  22. Chew T, Noyce R, Collins SE, Hancock MH, Mossman KL. Characterization of the interferon regulatory factor 3-mediated antiviral response in a cell line deficient for IFN production. Mol Immunol 2009;46:393–399 [CrossRef][PubMed]
    [Google Scholar]
  23. Zheng M, Wang P, Song W, Lau SY, Liu S et al. An A14U substitution in the 3' noncoding region of the M segment of viral RNA supports replication of influenza virus with an NS1 deletion by modulating alternative splicing of M segment mRNAs. J Virol 2015;89:10273–10285 [CrossRef][PubMed]
    [Google Scholar]
  24. Chung DH, Golden JE, Adcock RS, Schroeder CE, Chu YK et al. Discovery of a broad-spectrum antiviral compound that inhibits pyrimidine biosynthesis and establishes a type 1 interferon-independent antiviral state. Antimicrob Agents Chemother 2016;60:4552–4562 [CrossRef][PubMed]
    [Google Scholar]
  25. Cheng G, Wang L-CS, Fridlender ZG, Cheng GS, Chen B et al. Pharmacologic activation of the innate immune system to prevent respiratory viral infections. Am J Respir Cell Mol Biol 2010;1–29
    [Google Scholar]
  26. Es-Saad S, Tremblay N, Baril M, Lamarre D. Regulators of innate immunity as novel targets for panviral therapeutics. Curr Opin Virol 2012;2:622–628 [CrossRef][PubMed]
    [Google Scholar]
  27. Smee DF, Hurst BL, Day CW. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 2012;22:263–272 [CrossRef][PubMed]
    [Google Scholar]
  28. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 2011;85:6548–6556 [CrossRef][PubMed]
    [Google Scholar]
  29. Smee DF, Mckernan PA, Nord LD, Willis RC, Petrie CR et al. Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity. Antimicrob Agents Chemother 1987;31:1535–1541 [CrossRef][PubMed]
    [Google Scholar]
  30. Smee DF, von Itzstein M, Bhatt B, Tarbet EB. Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs. Antimicrob Agents Chemother 2012;56:6328–6333 [CrossRef][PubMed]
    [Google Scholar]
  31. Zheng B, Chan K, Lin Y, Zhao G, Chan C et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1. Virus 2008
    [Google Scholar]
  32. Wang P, Song W, Mok BW, Zhao P, Qin K et al. Nuclear factor 90 negatively regulates influenza virus replication by interacting with viral nucleoprotein. J Virol 2009;83:7850–7861 [CrossRef][PubMed]
    [Google Scholar]
  33. Kok KH, Lui PY, Ng MH, Siu KL, Au SW et al. The double-stranded RNA-binding protein PACT functions as a cellular activator of RIG-I to facilitate innate antiviral response. Cell Host Microbe 2011;9:299–309 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000758
Loading
/content/journal/jgv/10.1099/jgv.0.000758
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error